DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $944,517 | -10.7% | 3,807 | -13.7% | 0.05% | -6.0% |
| Q2 2023 | $1,058,160 | -61.1% | 4,409 | -59.1% | 0.05% | -63.5% |
| Q1 2023 | $2,720,009 | -11.0% | 10,792 | -6.3% | 0.14% | -16.0% |
| Q4 2022 | $3,056,581 | -0.1% | 11,516 | -2.8% | 0.16% | -6.9% |
| Q3 2022 | $3,061,000 | -3.5% | 11,850 | -5.3% | 0.18% | +3.6% |
| Q2 2022 | $3,173,000 | -85.6% | 12,514 | -83.3% | 0.17% | -83.4% |
| Q1 2022 | $21,970,000 | -13.4% | 74,896 | -2.8% | 1.02% | -7.9% |
| Q4 2021 | $25,363,000 | +9.6% | 77,092 | +1.5% | 1.11% | -1.0% |
| Q3 2021 | $23,134,000 | +13.0% | 75,988 | -0.4% | 1.12% | +11.3% |
| Q2 2021 | $20,472,000 | +19.9% | 76,286 | +0.5% | 1.00% | +8.8% |
| Q1 2021 | $17,079,000 | -12.0% | 75,877 | -13.1% | 0.92% | -15.0% |
| Q4 2020 | $19,402,000 | +3.0% | 87,341 | -0.1% | 1.09% | -5.8% |
| Q3 2020 | $18,834,000 | +21.0% | 87,464 | -0.6% | 1.15% | +13.9% |
| Q2 2020 | $15,560,000 | -9.9% | 87,992 | -29.5% | 1.01% | -21.3% |
| Q1 2020 | $17,269,000 | -15.5% | 124,769 | -6.3% | 1.29% | +8.4% |
| Q4 2019 | $20,426,000 | +8.8% | 133,087 | +2.4% | 1.19% | +1.3% |
| Q3 2019 | $18,775,000 | +3.2% | 129,991 | +2.1% | 1.17% | +1.2% |
| Q2 2019 | $18,193,000 | +9.0% | 127,293 | +0.7% | 1.16% | +3.5% |
| Q1 2019 | $16,684,000 | +26.3% | 126,372 | -1.3% | 1.12% | +13.4% |
| Q4 2018 | $13,208,000 | -5.7% | 128,090 | -0.6% | 0.99% | +7.9% |
| Q3 2018 | $14,005,000 | +10.1% | 128,892 | -0.0% | 0.91% | +5.2% |
| Q2 2018 | $12,725,000 | +1.6% | 128,954 | +0.8% | 0.87% | -0.8% |
| Q1 2018 | $12,528,000 | +3.6% | 127,955 | -1.8% | 0.88% | +8.1% |
| Q4 2017 | $12,092,000 | +10.6% | 130,282 | +2.2% | 0.81% | +4.7% |
| Q3 2017 | $10,935,000 | +1.2% | 127,489 | -0.4% | 0.77% | -2.6% |
| Q2 2017 | $10,802,000 | +4238.2% | 128,001 | +4291.1% | 0.80% | +4084.2% |
| Q1 2017 | $249,000 | +13.2% | 2,915 | +3.1% | 0.02% | +11.8% |
| Q4 2016 | $220,000 | -17.0% | 2,828 | -16.4% | 0.02% | -19.0% |
| Q3 2016 | $265,000 | -22.5% | 3,383 | 0.0% | 0.02% | -25.0% |
| Q2 2016 | $342,000 | +2.4% | 3,383 | -3.9% | 0.03% | +3.7% |
| Q1 2016 | $334,000 | +2.1% | 3,521 | 0.0% | 0.03% | 0.0% |
| Q4 2015 | $327,000 | +3.8% | 3,521 | -4.7% | 0.03% | 0.0% |
| Q3 2015 | $315,000 | -23.9% | 3,696 | -23.5% | 0.03% | -18.2% |
| Q2 2015 | $414,000 | +0.7% | 4,829 | 0.0% | 0.03% | 0.0% |
| Q1 2015 | $411,000 | -2.6% | 4,829 | -1.9% | 0.03% | 0.0% |
| Q4 2014 | $422,000 | +9.3% | 4,921 | -3.4% | 0.03% | +6.5% |
| Q3 2014 | $386,000 | -3.7% | 5,093 | -0.2% | 0.03% | -3.1% |
| Q2 2014 | $401,000 | +2.3% | 5,103 | -2.5% | 0.03% | -3.0% |
| Q1 2014 | $392,000 | -7.5% | 5,233 | -4.7% | 0.03% | -8.3% |
| Q4 2013 | $424,000 | +11.3% | 5,491 | 0.0% | 0.04% | +2.9% |
| Q3 2013 | $381,000 | +8.2% | 5,491 | -1.3% | 0.04% | +6.1% |
| Q2 2013 | $352,000 | – | 5,566 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |